AUTHORS
Mamta P Sumi, PhD, Dongxu Jiang, PhD2, Yahan Zhang, MS3, Daniel J Vail, PhD4, Kacey O'Donnell5, Shinjini Ganguly6, Jaroslaw P. Maciejewski, MD, PhD, FACP7, Omar Mian8, Babal Kant Jha, PhD9
AFFILIATIONS
1 Cancer Sciences, Cleveland Clinic Research, Cleveland, Ohio, United States
2 Cancer Sciences, Cleveland Clinic Research, Cleveland, Ohio, United States
3 Cancer Sciences, Cleveland Clinic Research, Cleveland, Ohio, United States
4 Cancer Sciences, Cleveland Clinic Research, Cleveland, Ohio, United States
5 Cancer Sciences, Cleveland Clinic Research, Cleveland, Ohio, United States
6 Cleveland Clinic Research, Cleveland, Ohio, United States
7 Taussig Cancer Center, Cleveland Clinic Research, Cleveland, Ohio, United States
8 Department of Radiation Oncology, University of Washington, Fred Hutch Cancer Center, Seattle, Washington, United States
9 Cancer Sciences, Cleveland Clinic Research, Cleveland, Ohio, United States
ABSTRACT
Background: MBD2 is a methyl-CpG-binding protein that recognizes DNA/chromatin and regulates gene expression through the NuRD corepressor complex. Our previous study showed that TET2 deficiency promotes regional hypermethylation and aberrant recruitment of MBD2/NuRD, causing transcriptional repression of differentiation-promoting genes (Jiang et al., Blood 2023). However, mechanisms by which MBD2 coordinates chromatin remodeling and modulates transcription in TET2-deficient myeloid disease remain unclear. We hypothesized that integrated multi-omics would resolve MBD2-regulated genes and identify chromatin-associated protein networks following TET2 loss.
Methods: We performed MBD2 chromatin immuno-precipitation (ChIP) in WT and Tet2-/- and RNA-seq of WT, Tet2-/- ,Mbd2-/- and Tet2-/-; Mbd2-/- murine HSPCs. In K562 human cell models, MBD2 ChIP, ATAC- and RNA-seq were performed in KO1 (non-targeting control WT) and K18 isogeneic TET2ko cells. MBD2 IP-MS defined TET2-dependent changes in the MBD2-associated proteome. Effects of MBD2 knock out and ectopic expression of TET2 in SIG-M5 AML cell line derived from TET2 knock out patinets were used for differentiation profile using flow cytometry.
Results: MBD2 ChIP showed largely conserved binding landscape between WT and Tet2-/- murine LSK cells, with 6,342 shared targets in females and 5,933 in males, plus limited genotype-specific binding. In contrast, in malignant cells there were context-dependent MBD2 occupancy. We observed 479 common while 283 distinct genes were enriched in TET2-ko cells. Distinct peak include myeloid loci (CEBPB, MCL1). ATAC-seq showed similar global accessibility between WT and TET2-ko cells, indicating that TET2 deficiency does not induce widespread accessibility changes but promotes selective regulatory alterations. Integration of ChIP and RNA-seq we identified MBD2-regulated genes. In murine cells, CD74, IL6RA, ZBTB7B, and NFE2L1 showed increased MBD2 occupancy leading downrgulation in Tet2ko.
Interestingly, deletion of MBD2 restored gene expression and homeostatic hematopoeisis in Tet2ko HSPCs, supporting specificity of MBD2-mediated repression. In TET2ko SIG-M5 cells, MBD2 loss induced broad transcriptional reprogramming (726 genes enriched in MBD2-KO;263 in parental;> 2-fold, adjusted P≤0.05),with enrichment of myeloid differentiation genes. By contrast, TET2 re-expression produced a more selective response (98 genes enriched inTET2 -OE; 27 in parental), increased CD209 (37-fold; FDR=6.7×10-4) and ITGAX/CD11c (8-fold; FDR=0.023), and enriched inflammatory (NES 2.0) programs. Flow cytometry demonstrated a myeloid differentiation phenotype evidenced by increased terminal differentiation markers, CD11b CD14 and CD15 in TET2 over expressing SIGM5. IP-MS revealed extensive remodeling of the MBD2-associated proteome following TET2 loss. TET2-deficient cells showed increased peptide representation of select NuRD complex components including HDAC2 (3-fold), MTA3 (3-fold),CHD3 (2-fold),GATAD2A (2-fold) and GATAD2B (2-fold). TET2-KO-specific MBD2-associated proteins also included non-NuRD chromatin/transcriptional regulators (KDM1A, SMARCD1/3, CARM1), indicating expansion of the MBD2 regulatory network beyond classical NuRD in TET2ko cells.
Conclusions: Our integrated multi-omics support a model in which MBD2 functions as a context-dependent transcriptional repressor in TET2-deficient myeloid cells, rather than broad chromatin accessibility remodeling, TET2 loss associate with selective changes in MBD2 occupancy on tumor suppressors and lineage-defining transcription hubs. Global chromatin accessibility is largely identical between wild-type and TET2-KO cells, indicating that TET2 loss triggers targeted, rather than system-wide, regulatory alterations. These changes were linked to repression of specific target genes. MBD2 loss restored differentiation-associated myeloid transcriptional programs, similar to restoring TET2 expression in TET2ko leukemic cells. In both scenarios, strong differentiation-associated phenotypes were observed. Together, these findings extend the TET2-MBD2/NuRD model and identify additional MBD2-associated chromatin regulators that may contribute to transcriptional dysregulation in TET2-mutant myeloid neoplasia. These findings also suggest that these changes are reversible by targeting both TET2 and MBD2, potentially introducing new therapeutic avenues.
DISCLOSURES
Mamta P Sumi, PhD: No relevant conflicts of interest to declare.